KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Gains from Investment Securities (2016 - 2026)

Gsk has reported Gains from Investment Securities over the past 18 years, most recently at -$8.1 million for Q1 2026.

  • For Q1 2026, Gains from Investment Securities rose 70.81% year-over-year to -$8.1 million; the TTM value through Mar 2026 reached -$149.3 million, up 18.88%, while the annual FY2025 figure was -$122.4 million, 7.43% up from the prior year.
  • Gains from Investment Securities for Q1 2026 was -$8.1 million at Gsk, up from -$53.2 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at -$8.1 million in Q1 2026 and troughed at -$73.2 million in Q4 2023.
  • A 5-year average of -$49.2 million and a median of -$60.3 million in 2024 define the central range for Gains from Investment Securities.
  • Biggest five-year swings in Gains from Investment Securities: decreased 21.35% in 2025 and later surged 70.81% in 2026.
  • Year by year, Gains from Investment Securities stood at -$69.2 million in 2022, then fell by 5.82% to -$73.2 million in 2023, then grew by 17.62% to -$60.3 million in 2024, then grew by 11.8% to -$53.2 million in 2025, then soared by 84.8% to -$8.1 million in 2026.
  • Business Quant data shows Gains from Investment Securities for GSK at -$8.1 million in Q1 2026, -$53.2 million in Q4 2025, and -$27.7 million in Q1 2025.